NEW DELHI: A parliamentary committee has recommended that the price caps enforced by the govt, for example, the existing 30% trade margin cap on 42 essential anti-cancer drugs - should be extended to cover cancer vaccines , immunotherapy, and oral chemotherapy . It has also suggested that quality of generic drugs available in the market should be monitored citing hesitancy among medical professionals in prescribing them.
According to the committee, headed by Narain Dass Gupta, though the govt has taken significant steps in recent years towards strengthening the regulatory framework for governing the pricing of cancer drugs and promoting affordability, a substantial segment of such drugs remains beyond the ambit of current price control mechanisms.
"The number of anti-cancer medicines under price control has increased from 40 (in 2011) to 63 (in 2022), still, a significant number of oncology medications are not included under the Drugs (Prices Control) Order, 2013, and thus are not subject to any statutory price ceiling," the committee has pointed out and said that this regulatory non-inclusion has led to excessive and often unaffordable pricing.
"In view of this, the committee strongly recommends that the govt undertake urgent measures to expand the scope of the DPCO to include the widest possible range of cancer drugs," the committee on petitions has recommended.
According to the committee, headed by Narain Dass Gupta, though the govt has taken significant steps in recent years towards strengthening the regulatory framework for governing the pricing of cancer drugs and promoting affordability, a substantial segment of such drugs remains beyond the ambit of current price control mechanisms.
"The number of anti-cancer medicines under price control has increased from 40 (in 2011) to 63 (in 2022), still, a significant number of oncology medications are not included under the Drugs (Prices Control) Order, 2013, and thus are not subject to any statutory price ceiling," the committee has pointed out and said that this regulatory non-inclusion has led to excessive and often unaffordable pricing.
"In view of this, the committee strongly recommends that the govt undertake urgent measures to expand the scope of the DPCO to include the widest possible range of cancer drugs," the committee on petitions has recommended.
You may also like
Direct flight between India and China, Mansarovar Yatra, peace on the border... these issues were discussed between PM Modi and Xi Jinping
Newcastle identify third target to replace Alexander Isak after Liverpool transfer agreement
Kolo Muani move, Lookman hijack - Tottenham's best and worst case transfer deadline day scenarios
Monsoon fury batters Pakistan, Khyber Pakhtunkhwa worst hit
Jeremy Clarkson issues four-word Kimi Antonelli defence after Jacques Villeneuve attack
